CTRI/2023/01/048893尚未招募2 期
Randomized double blind placebo-controlled clinical trial â?? an exploratory study to investigate the efficacy of moclobemide as an add-on treatment in castration-resistant prostate cancer patients
ICMR-Product Development Centre at AIIMS New Delhi0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Age>=18 years
- •2.Castration-resistant prostate cancer patients (CRPC): Disease progression despite androgen-deprivation therapy (ADT) and may present as one or any combination of a continuous rise in serum levels of prostate-specific antigen (PSA), progression of pre-existing disease, or appearance of new metastases (Ga-68-PSMA PET/CT Scan) and characterized by low levels of testosterone ( <50 ng/dl).
排除标准
- •1.Patients who are not willing to participate
- •2.Active psychiatric illnesses that would limit compliance with protocol requirements
- •3.Patients taking tricyclic/tetracyclic antidepressants or selective serotonin reuptake inhibitors, or serotonin norepinephrine reuptake inhibitors or conventional monoamine oxidase inhibitors or thioridazine or dextromethorphan or bupropion or triptans or tramadol or meperidine or selegiline or any antipsychotic drugs or sympathomimetic drugs or linezolid
- •4.Patients with connective tissue disorders like systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis and other autoimmune disorders
- •5.Patients with hepatic dysfunction that is those in whom serum bilirubin will be more than 1.5 and, AST and ALT will be more than 2.5 fold higher than the upper limit of normal
- •6.Patients in whom serum creatinine will be more than 1.5 fold higher than the upper limit of normal
- •7.Patients with congestive cardiac failure, severe or unstable angina or thyrotoxicosis
- •8.Atrial Fibrillation, or other cardiac arrhythmia requiring medical therapy
- •9.Administration of any other investigational therapeutic agent within 30 days of screening
- •10.Prior radiation therapy completed < 4 weeks prior to enrolment
- •11.Any currently active second malignancy
- •12.Patients in whom urgent chemotherapy, in the opinion of the treating physician, is indicated
- •13.Patients taking strong CYP2D6, CYP2C19 and CYP3A4 inducer or inhibitor, available from Metabolism and Transport Drug Interaction Database (http://www.druginteractioninfo.org)
- •14.Pheochromocytoma
- •15.Carcinoid Syndrome
- •16.Angle-closure glaucoma
研究者
相似试验
进行中（未招募）
1 期
The effect of EA-230 on the immuneresponseEUCTR2014-002481-78-NLExponential Biotherapies Inc60
已完成
不适用
Randomized double blind placebo-controlled clinical safety, tolerability and pharmacokinetic/-dynamic study on the effects of escalating single intravenous doses of EA-230 on the innate immune response during experimental human endotoxemiaNL-OMON40791Exponential Biotherapies inc.60
尚未招募
1 期
Randomized double-blind placebo-controlled clinical trial of Jiangtang Xiaozhi decoction for the management of metabolic-associated fatty liver diseasemetabolic-dysfunction-associated fatty liver diseaseITMCTR2024000161Xiyuan Hospital, China Academy of Chinese Medical Sciences
尚未招募
1 期
Randomized double-blind placebo-controlled clinical observation and central mechanism of acupoint catgut embedding in the treatment of chronic spontaneous urticariaChronic spontaneous urticarialITMCTR2200006839Guang 'anmen Hospital
已完成
4 期
Medical management of compartment syndromeCTRI/2012/11/003089Christian Medical College Vellore40